Business News

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus today announced a large-scale research collaboration designed to advance the field of human genetics and precision medicine through the sharing of 450,000 DNA samples and corresponding health records from de-identified, consented patient participants in …

Read More »

AbbVie Completes Transformative Acquisition of Allergan

NORTH CHICAGO, Ill., May 8, 2020 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. “We are pleased to reach …

Read More »

PTC Therapeutics to Acquire Censa Pharmaceuticals and its Phase 3 PKU Candidate

SOUTH PLAINFIELD, N.J., May 6, 2020 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other …

Read More »

Alexion Acquires Portola Pharmaceuticals for $1.4 Billion

BOSTON & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a definitive merger agreement for Alexion to acquire Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Portola’s commercialized medicine, Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya® in Europe, is …

Read More »

AVROBIO Collaborates with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a new development and commercialization agreement with Saladax Biomedical, Inc. (Saladax), a leading diagnostics provider focused on developing blood tests for personalized dosing, to …

Read More »

Vaxxel Acquires Transgene’s DuckCelt-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses

Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s (Paris:TNG) proprietary DuckCelt®-T17 cell line. The terms of the agreement are confidential. Through this agreement, Transgene becomes a shareholder of Vaxxel. DuckCelt®-T17, initially developed and patented by Transgene, is an avian cell line grown in …

Read More »

BioMarin Enter a Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies

SAN RAFAEL, Calif., May 3, 2020 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an …

Read More »

Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate

SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability …

Read More »

Denovo Biopharma To Acquire Tocagen’s Entire Replicating Gene Therapy Platform and Related Assets

SAN DIEGO, April 28, 2020 /PRNewswire/ — Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it is acquiring Tocagen’s retroviral replicating vector platform (RRV) in its entirety, including its investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC (now …

Read More »

Vertex and Affinia Enter $1.6 Billion Collaboration Focused on Novel AAV Capsids for Genetic Therapies

BOSTON & WALTHAM, Mass.–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and Affinia Therapeutics announced today that the two companies have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids to deliver transformative genetic therapies to people with serious diseases. Affinia Therapeutics’ proprietary AAVSmartLibrary and associated technology provides capsids …

Read More »